


CRYO
CAP
CELL



Press Release

CryoCapCell raises €1.5 million from Seventure Partners' Quadrivium 1 seed capital fund

The company has developed a globally unique technology for ultra-rapid, high-pressure vitrification, linking live pre-microscopy with electronic post-microscopy

Paris, January 31st 2017 – CryoCapCell, a company that develops and markets disruptive technologies for high-pressure vitrification, announced today a €1.5 million fund raising from the Quadrivium 1 seed capital fund managed by Seventure Partners.

Thanks to this funding, CryoCapCell will continue the development and commercial deployment of its correlative microscopy technologies using high-pressure vitrification (or “cryogenisation”), a unique process which prevents the alteration of biological structures, initially for electron-microscopy in the field of cancer research.

Xavier Heiligenstein, co-founder of CryoCapCell, explains: *“In the battle against cancer, the understanding of living tissue requires dynamic, high-resolution observation on multiple scales. To help establish a precise relationship between cell morphology and function, our high-pressure vitrification technology, combined with dynamic observation tools, becomes a central element in the analysis of the biological mechanisms that underlie cancerous disorders. Our technology allows live monitoring of a biological event, thanks to a photonic microscope, followed by the vitrification of the sample in less than two seconds.”*

The development of this proprietary technology has benefited from the support of the Institut Curie’s (CNRS – UMR144) and Arts et Metier’s (PIMM – CNRS UMR8006) partners, and from a solid industrial network in the Clermont-Ferrand region.

Philippe Tramoy, Investment Director at the Quadrivium 1 seed capital fund at Seventure Partners, says: *“The high-pressure vitrification technology combined with optical microscopy designed by CryoCapCell is a truly disruptive innovation: it will allow scientists to better explore living samples,*

thus opening up completely new areas of research and application, which could have a significant impact on the study and development of biological structures.”

CryoCapCell is initially targeting research laboratories using correlative microscopy, an approach that aims to understand the relationship between a biological structure and its function. This is an indispensable process, particularly in the study of tumours.

About CryoCapCell

Created in 2013 by Jérôme Heiligenstein and his son Xavier - who has a PhD in biology and specialises in cryogenic methods for electron microscopy in biology - CryoCapCell designs, develops and globally markets unique, proprietary technologies for high-pressure vitrification. Thanks to the highly innovative nature of its technologies, CryoCapCell has developed partnerships with leading scientific research institutions, including Institut Curie and the Mechanical and Materials Engineering Laboratory (PIMM) at Arts et Metiers.

For more information, www.cryocapcell.com

About Seventure Partners

As an active partner of innovative companies with high growth potential, Seventure Partners has been investing since 1997 in two main areas of activity: Digital technologies, particularly fintech and assurtech, in France, Germany and Luxembourg, and Life Sciences Throughout Europe and North America. Managing more than € 660 million as of December 31st 2015, Seventure Partners is emerging as one of Europe's leading innovation capital players. In the field of life sciences, Seventure Partners invests mainly in four areas: medicines, medical equipment and connected health, industrial biotechnology, and companies active in the well-being, nutritional health and FoodTech sectors, with a particular focus on applications of discoveries relating to the microbiome. Seventure Partners has supported the development of companies from the first round and even the seeding, up to technological capital development financing rounds with tickets from € 500K to € 10m per financing round and up to € 20m per company. Seventure Partners is a subsidiary of Natixis Global Asset Management. Natixis is the finance, management and financial services arm of Groupe BPCE.

To learn more, go to www.seventure.fr / Twitter @SeventureP

About the seed fund Quadrivium 1

The Quadrivium 1 Seed Fund is one of the capital-innovation funds managed by Seventure Partners. This fund finances French companies in the start-up phase (FNA - Program d'Investissement d'Avenir) in the fields of life sciences and digital technologies, which come from or are linked to the academic center federated around UPMC, University Paris II, the National Museum of Natural History, IRCAM, ENSCI, Technological University of Compiègne, CNRS, Institut Curie, Fondation Pierre Gilles de Gennes, Fondation Voir et Entendre and Paris Science and Letters (PSL).

Contacts:

CryoCapCell:

Martin Belle – contact@cryocapcell.com - +33 1 44 24 62 51

Media – NewCap:

Annie-Florence Loyer – afloyer@newcap.fr - +33 1 44 71 02 12 /+33 6 88 20 35 59

Seventure Partners Quadrivium 1 seed capital fund:

Philippe Tramoy - philippe.tramoy@seventure.fr – +33 1 58 19 83 26

Raïssa Brian - raissa.brian@seventure.fr - +33 1 58 19 33 56